Pharmacokinetic drug-drug interactions in the intensive care unit - single-centre experience and literature review - PubMed (original) (raw)
Review
doi: 10.5603/AIT.a2017.0053. Epub 2017 Oct 13.
Affiliations
- PMID: 29027654
- DOI: 10.5603/AIT.a2017.0053
Free article
Review
Pharmacokinetic drug-drug interactions in the intensive care unit - single-centre experience and literature review
Piotr Łój et al. Anaesthesiol Intensive Ther. 2017.
Free article
Abstract
Background: Drug-drug interactions constitute a serious health hazard in everyday clinical practice in critically ill patients. Drug-drug interactions may be pharmacokinetic or pharmacodynamic in their nature. We aimed to investigate the quantity and quality of possible drug-drug interactions, and their possible side effects in intensive care unit patients in a 12-month period.
Methods: This retrospective study covered data on pharmacological treatment of 43 consecutive patients (11 females, 32 males) aged 62 ± 15 years, hospitalized between January 2015 and February 2016. Pharmacokinetic DDIs were identified and graded. Only severe and clinically important drug-drug interactions were subjected for further analysis.
Results: Median baseline SAPS III was 53 (IQR 38-67) points. Median intensive care unit stay was 12 (6-25) days. Subjects were treated with a median number of 22 (12-27) drugs. We identified 27 (16-41) possible drug-drug interactions per patient, including 3 (1-7) drug-drug interactions of a severe grade. The total number of severe and clinically important drug-drug interactions was 253 of which 227 were analyzed in detail. No possible side-effects of drug-drug interactions were identified.
Conclusions: DDIs as well as their side-effects are challenging regarding their precise evaluation, especially due to the need for multidrug treatment in critically ill patients. Concentration-controlled therapy should be recommended, especially for treatment with vancomycin, digoxin and valproate. Pantoprazole should be a proton pump-inhibitor of choice. Drug dose modification is necessary in combined treatment with fluconazole and amiodarone or rifampicin. From a clinical point of view, the most important impact of drug-drug interactions is on antibiotic treatment effectiveness, especially with meropenem when valproate is also prescribed.
Keywords: drug-drug interactions; intensive care unit; pharmacokinetics.
Similar articles
- Potential drug-drug interactions and nephrotoxicity in hematopoietic stem cell transplant adult recipients during bone marrow transplantation unit stay.
Sanchez L, Bacle A, Lamy T, Le Corre P. Sanchez L, et al. Cancer Chemother Pharmacol. 2019 May;83(5):827-835. doi: 10.1007/s00280-019-03791-9. Epub 2019 Feb 13. Cancer Chemother Pharmacol. 2019. PMID: 30758649 - Potential drug-drug interactions associated with prolonged stays in the intensive care unit: a retrospective cohort study.
Moura C, Prado N, Acurcio F. Moura C, et al. Clin Drug Investig. 2011;31(5):309-16. doi: 10.1007/BF03256929. Clin Drug Investig. 2011. PMID: 21344954 - Comparison of two databases to detect potential drug-drug interactions between prescriptions of HIV/AIDS patients in critical care.
Ramos GV, Guaraldo L, Japiassú AM, Bozza FA. Ramos GV, et al. J Clin Pharm Ther. 2015 Feb;40(1):63-7. doi: 10.1111/jcpt.12222. Epub 2014 Oct 20. J Clin Pharm Ther. 2015. PMID: 25329640 - Drug absorption, distribution, metabolism and excretion considerations in critically ill adults.
Roberts DJ, Hall RI. Roberts DJ, et al. Expert Opin Drug Metab Toxicol. 2013 Sep;9(9):1067-84. doi: 10.1517/17425255.2013.799137. Epub 2013 May 17. Expert Opin Drug Metab Toxicol. 2013. PMID: 23682923 Review. - [Drug interactions in intensive care medicine].
Peters H, Sakka SG. Peters H, et al. Anasthesiol Intensivmed Notfallmed Schmerzther. 2014 May;49(5):326-34; quiz 335. doi: 10.1055/s-0034-1376452. Epub 2014 May 26. Anasthesiol Intensivmed Notfallmed Schmerzther. 2014. PMID: 24863334 Review. German.
Cited by
- The Issue of Pharmacokinetic-Driven Drug-Drug Interactions of Antibiotics: A Narrative Review.
Cattaneo D, Gervasoni C, Corona A. Cattaneo D, et al. Antibiotics (Basel). 2022 Oct 13;11(10):1410. doi: 10.3390/antibiotics11101410. Antibiotics (Basel). 2022. PMID: 36290068 Free PMC article. Review. - The Prevalence of Selected Potential Drug-Drug Interactions of Analgesic Drugs and Possible Methods of Preventing Them: Lessons Learned From the Analysis of the Real-World National Database of 38 Million Citizens of Poland.
Kardas P, Urbański F, Lichwierowicz A, Chudzyńska E, Czech M, Makowska K, Kardas G. Kardas P, et al. Front Pharmacol. 2021 Jan 18;11:607852. doi: 10.3389/fphar.2020.607852. eCollection 2020. Front Pharmacol. 2021. PMID: 33536918 Free PMC article. - Current clinical use of intravenous fosfomycin in ICU patients in two European countries.
Putensen C, Ellger B, Sakka SG, Weyland A, Schmidt K, Zoller M, Weiler N, Kindgen-Milles D, Jaschinski U, Weile J, Lindau S, Kieninger M, Faltlhauser A, Jung N, Teschendorf P, Adamzik M, Gründling M, Wahlers T, Gerlach H, Litty FA. Putensen C, et al. Infection. 2019 Oct;47(5):827-836. doi: 10.1007/s15010-019-01323-4. Epub 2019 Jun 12. Infection. 2019. PMID: 31190298 Clinical Trial. - Studies on Chemical Characterization of Ginkgo Amillaria Oral Solution and Its Drug-Drug Interaction With Piceatannol 3'-_O_-_β_-D-Glucopyranoside for Injection.
Yu Z, Hu X, Zhou L, Chen H, Xing Y, Han C, Ding H, Han L, Pan G, Fu Z. Yu Z, et al. Front Pharmacol. 2022 Jul 19;13:932646. doi: 10.3389/fphar.2022.932646. eCollection 2022. Front Pharmacol. 2022. PMID: 35928280 Free PMC article. - Clinically Relevant Interactions with Anti-Infectives on Intensive Care Units-A Multicenter Delphi Study.
Koeck JA, Hilgarth H, von Ameln-Mayerhofer A, Meyn D, Warlich R, Münstedt A, Horn D, König C. Koeck JA, et al. Antibiotics (Basel). 2021 Oct 31;10(11):1330. doi: 10.3390/antibiotics10111330. Antibiotics (Basel). 2021. PMID: 34827267 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical